Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Targacept Inc.
ClinicalTrials.gov Identifier:
NCT01293669
First received: February 9, 2011
Last updated: September 3, 2013
Last verified: July 2012

February 9, 2011
September 3, 2013
January 2011
January 2012   (final data collection date for primary outcome measure)
Changes in fasting plasma glucose (FPG) [ Time Frame: Day 1 and Week 4 ] [ Designated as safety issue: No ]
The primary efficacy endpoint will be FPG values obtained at Week 4 compared to Day 1 (baseline). This change from baseline will be analyzed using MMRM techniques with an alpha of 0.10 (one-sided), to examine differences between the TC-6987 and placebo treatment cohorts. This change from baseline will be analyzed using the primary efficacy endpoints for the mITT analysis set. The efficacy analyses based on the Per Protocol (PP) analysis set will be considered secondary.
Same as current
Complete list of historical versions of study NCT01293669 on ClinicalTrials.gov Archive Site
  • Change in FPG from Day 1 (Baseline) at each time point [ Time Frame: Day 1, Week 1 and Week 4 ] [ Designated as safety issue: No ]
    Change in FPG from Day 1 (Baseline) compared to weeks 1 and 4
  • Change in FPG and insulin from Day 1 (Baseline) at each time point [ Time Frame: Day 1, Week 1 and Week 4 ] [ Designated as safety issue: No ]
    Change in FPG and insulin from Day 1 (Baseline) compared to weeks 1 and 4
  • Change in AUC FPG from Day 1 (Baseline) and at Week 4 [ Time Frame: Day 1 and Week 4 ] [ Designated as safety issue: No ]
    Change in AUC FPG from Day 1 (Baseline) compared to weeks 1 and 4
  • Change in AUC insulin from Day 1 (Baseline) at Week 4 [ Time Frame: Day 1 and Week 4 ] [ Designated as safety issue: No ]
    Change in AUC insulin from Day 1 (Baseline) compared to week 4
Same as current
Not Provided
Not Provided
 
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus

TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has demonstrated potent anti-inflammatory/antioxidant properties in animal models. Following the oral administration of a 1mg/kg dose of TC-6987 to diabetic mice (db/db mouse) for 7 weeks, numerous metabolic improvements were observed. Specifically, plasma glucose and triglyceride concentrations declined by approximately 30%; Hb1Ac was reduced by nearly 50%; and TNF-α declined more than 60% relative to control db/db mice Therefore, it appears that TC-6987 could prove beneficial in reducing elevated glucose concentrations in diabetic patients as well as in ameliorating organ damage associated with inflammation, oxidative stress and hyperglycemia.

This is a Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy, safety, tolerability, and pharmacokinetic parameters of TC-6987 in subjects with type 2 diabetes mellitus (T2DM). The study is organized into three phases: (a) Screening phase consisting of a 1-week Screening (Week -5)and a 4-week Washout (Week -4 to Day 1); (b) 4-week, Double-Blind Treatment (Day 1 to Week 4) during which subjects are randomized to either TC-6987 (20 mg on Day 1 and 10 mg from Day 2 to Week 4) or placebo; and (c) 2-week Follow-Up (Week 6). Unscheduled visits will be allowed between visits from Washout through Follow-up to evaluate a subject's glycemic status or other safety issues, as required. Subjects will fast overnight for a minimum of 10 hrs and refrain from drinking alcohol 24 hrs prior to each visit.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: TC-6987
    TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
  • Drug: Placebo
    Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
  • Experimental: TC-6987
    Intervention: Drug: TC-6987
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
440
January 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or postmenopausal/surgically sterile females
  • Being treated for T2DM with oral antidiabetic agents (excluding glitazones)
  • BMI limit ≤ 38
  • Subjects at least 80% compliant on reporting daily SMBG values during washout
  • At the end of washout the subject's fasting SMBG is higher than it was at the start of washout and the fasting SMBG ≤ 280.g treated for T2DM with oral antidiabetic agents (excluding glitazones)

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Severe complications of T2DM (especially diabetic retinopathy imminently requiring treatment for preserving or restoring vision, diabetic neuropathy with symptomatic orthostatic hypotension, urinary retention, gastric stasis, or pedal ulcers)
  • Current treatment with insulin or a glitazone
  • Use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors
  • FSH level of < 35 IU/L and a LH level < 25 IU/L except for confirmed surgically sterile women with functioning ovaries
  • Significant cardiovascular diseases (including arrhythmia) or congestive heart failure, or severe ischemic disease within the last 3 months prior to Screening, or evidence of stroke, myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty
  • History of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, CV, GI, or urological disorder; or diagnosis of major depressive disorder; if stable medical disorder, any medical treatment must be stable for last 2 months prior to Screening
  • History of diabetic ketoacidosis
  • Patients who have an increased red blood cell (RBC) turn-over or thalassemia or anemia
  • Known HIV or history of viral hepatitis type B or C
  • Systemic infection with TB
  • Current or previous use of oral or injectable corticosteroids 3 months prior to screening.
  • Subject has persistent, uncontrolled severe hypertension as indicated by a systolic blood pressure > 180 mmHg or a diastolic blood pressure of > 110 mmHg, with or without treatment
  • Subject has had a malignancy in the last 5 years, except for successfully treated basal or squamous cell carcinoma of the skin or of the cervix
  • Subject is receiving chemotherapy
  • Tobacco user within 4 months prior to Screening
  • Smoking cessation therapy within 4 months prior to Screening and/or planned during the study
  • Use of prohibited concomitant medications including psychoactive agents
  • History within 6 months prior to Screening of alcohol abuse or illicit drug abuse
  • Was administered study medication in another clinical trial in the past 3 months prior to Screening
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01293669
TC-6987-23-CRD-002
No
Targacept Inc.
Targacept Inc.
Not Provided
Principal Investigator: Aaron Vinik, MD Strelitz Diabetes Center, Eastern Virginia Medical School
Targacept Inc.
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP